EPISODE · Jun 27, 2025 · 13 MIN
MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results
from MPR Weekly Dose
Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results
0:00
13:13
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 13 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on June 27, 2025.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!